Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400952 · ClinicalTrials.gov registry record · Phase 2
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
A Phase 2 study of Keratoconus, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07400952 is a Phase 2 study of Keratoconus that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 100 participants, below the 1,176-participant average among 21 other Keratoconus trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07400952, a Phase 2 study of Keratoconus, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
Conditions Studied
Interventions
- DRUG GLK-221 Ophthalmic Solution
- DRUG Placebo Ophthalmic Solution
Study Locations (1)
Ohio
- Glaukos Clinical Study Site - Westerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-12-23 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07400952
The ClinicalTrials.gov registry entry for NCT07400952 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,176-participant average among 21 other Keratoconus trials with a reported enrollment target (91% lower). The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratoconus appearing as the primary indexed condition, and to 2 interventions - of which GLK-221 Ophthalmic Solution is the first listed.
NCT07400952 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07400952 about?
NCT07400952 is a clinical study titled "Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus". Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
What is the current status of trial NCT07400952?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-12-23. Estimated completion is 2027-04.
What conditions does trial NCT07400952 study?
This clinical trial studies the following conditions: Keratoconus.
What interventions are being tested in trial NCT07400952?
The interventions under investigation include: GLK-221 Ophthalmic Solution (DRUG), Placebo Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT07400952?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07400952 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning
RECRUITING · Phase 2
-
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
RECRUITING · Phase 2
-
Comparison of Standard vs. Accelerated Corneal Crosslinking
RECRUITING · Phase 2
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
OCT in Diagnosis of Irregular Corneas
RECRUITING
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.